Approval · Notice of Compliance 37772 · 2026
OXLUMO: Notice of Compliance 37772
Issued June 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37772
- Date
- June 24, 2026
- Company
- Alnylam Netherlands B.V.Amsterdam, Netherlands
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the specification for the drug substance / Change in the specification for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OXLUMO | Not yet assigned | — |
Medicinal ingredients
- LUMASIRAN SODIUM 94.5 MG per 0.5ML